Abstract
The therapy of chronic inflammatory diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) has recently been enriched by the successful launch of the anti-cytokine biologicals Etanercept (tumor necrosis factor (TNF) receptor-p75 Fc fusion protein), Infliximab (chimeric anti-human TNF-α monoclonal antibody), Adalimumab (recombinant human anti-human TNF-α monoclonal antibody) and Anakinra (recombinant form of human interleukin 1β (IL-1) receptor antagonist) [1-3]. The success of these novel treatments has impressively demonstrated the clinical benefit that can be gained from therapeutic intervention in cytokine signalling, highlighting the central role of proinflammatory cytokine systems like IL-1β and TNF-α to be validated targets [4] However, all of the anti-cytokine biologicals available to date are proteins, and therefore suffering to a varying degree from the general disadvantages associated with protein drugs. Therefore, small molecular, orally active anti-cytokine agents, which target specific pathways of proinflammatory cytokines, would offer an attractive alternative to anti-cytokine biologicals. A number of molecular targets have been identified for the development of such small molecular agents but p38 mitogen-activated protein (MAP) kinase occupies a central role in the regulation of IL-1β and TNF-α signalling network at both the transcriptional and translational level [5, 6]. Since the mid-1990s, an immense number of inhibitors of p38 MAP kinase has been characterised in vitro, and to date several compounds have been advanced into clinical trials. This review will highlight the correlation between effective inhibition of p38 MAP kinase at the molecular target and cellular activity in functional assays of cytokine, particularly TNF-α and IL-1β production. SAR will be discussed regarding activity at the enzyme target, but also with regard to properties required for efficient in vitro and in vivo activity.
Keywords: N-Substituted Imidazoles, TNF alpha release, fused heterocycles, crystallisation, cytokine, anilinoquinazoline
Current Topics in Medicinal Chemistry
Title: New Approaches to the Treatment of Inflammatory Disorders Small Molecule inhibitors of p38 MAP Kinase
Volume: 6 Issue: 2
Author(s): Christian Peifer, Gerd Wagner and Stefan Laufer
Affiliation:
Keywords: N-Substituted Imidazoles, TNF alpha release, fused heterocycles, crystallisation, cytokine, anilinoquinazoline
Abstract: The therapy of chronic inflammatory diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) has recently been enriched by the successful launch of the anti-cytokine biologicals Etanercept (tumor necrosis factor (TNF) receptor-p75 Fc fusion protein), Infliximab (chimeric anti-human TNF-α monoclonal antibody), Adalimumab (recombinant human anti-human TNF-α monoclonal antibody) and Anakinra (recombinant form of human interleukin 1β (IL-1) receptor antagonist) [1-3]. The success of these novel treatments has impressively demonstrated the clinical benefit that can be gained from therapeutic intervention in cytokine signalling, highlighting the central role of proinflammatory cytokine systems like IL-1β and TNF-α to be validated targets [4] However, all of the anti-cytokine biologicals available to date are proteins, and therefore suffering to a varying degree from the general disadvantages associated with protein drugs. Therefore, small molecular, orally active anti-cytokine agents, which target specific pathways of proinflammatory cytokines, would offer an attractive alternative to anti-cytokine biologicals. A number of molecular targets have been identified for the development of such small molecular agents but p38 mitogen-activated protein (MAP) kinase occupies a central role in the regulation of IL-1β and TNF-α signalling network at both the transcriptional and translational level [5, 6]. Since the mid-1990s, an immense number of inhibitors of p38 MAP kinase has been characterised in vitro, and to date several compounds have been advanced into clinical trials. This review will highlight the correlation between effective inhibition of p38 MAP kinase at the molecular target and cellular activity in functional assays of cytokine, particularly TNF-α and IL-1β production. SAR will be discussed regarding activity at the enzyme target, but also with regard to properties required for efficient in vitro and in vivo activity.
Export Options
About this article
Cite this article as:
Peifer Christian, Wagner Gerd and Laufer Stefan, New Approaches to the Treatment of Inflammatory Disorders Small Molecule inhibitors of p38 MAP Kinase, Current Topics in Medicinal Chemistry 2006; 6 (2) . https://dx.doi.org/10.2174/156802606775270323
DOI https://dx.doi.org/10.2174/156802606775270323 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucocorticoids and their Effects on Bone and Joints in Rheumatoid Arthritis
Current Rheumatology Reviews Ligand Based-Pharmacophore Modeling and Extended Bi oactivity Prediction for Salinosporamide A, B and C from Marine Actino mycetes Salinispora tropica
Combinatorial Chemistry & High Throughput Screening Novel Molecular Targets for Systemic Lupus Erythematosus
Current Drug Targets Prediction of Citrullination Sites on the Basis of mRMR Method and SNN
Combinatorial Chemistry & High Throughput Screening Evidence for the Involvement of Resistin in Inflammation and Cardiovascular Disease
Current Diabetes Reviews Psychosomatic Features, Compliance and Complementary Therapies in Rheumatoid Arthritis
Current Rheumatology Reviews Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds
Current Medicinal Chemistry Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Physical Therapy Modalities in Management of Fibromyalgia
Current Pharmaceutical Design TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews Regulatory T Cells in Cancer Biology: A Possible New Target for Biochemical Therapies
Mini-Reviews in Medicinal Chemistry Probiotics in Curing Allergic and Inflammatory Conditions - Research Progress and Futuristic Vision
Recent Patents on Inflammation & Allergy Drug Discovery Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology Cardiovascular Risk Prediction using JBS3 Tool: A Kerala based Study
Current Medical Imaging CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets Structure, Function and Control of Complement C5 and its Proteolytic Fragments
Current Molecular Medicine The Innate Immune System and Fever under Redox Control: A Narrative Review
Current Medicinal Chemistry An Update on Clinical and Pharmacological Aspects of Drug-Eluting Stents
Cardiovascular & Hematological Disorders-Drug Targets Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued)